Advertisement
GlaxoSmithKline
Subscribe to GlaxoSmithKline

The Lead

GSK Expands Its Asthma and COPD Portfolio in the US

January 26, 2015 10:36 am | News | Comments

GlaxoSmithKline has announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has launched four inhaled respiratory therapies in the US, all delivered in its Ellipta inhaler.

Array BioPharm to Acquire Novartis’ Encorafenib

January 23, 2015 8:23 am | News | Comments

Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma...

Two Leading Ebola Vaccines Appear Safe, Further Tests Starting

January 9, 2015 8:14 am | by MARIA CHENG, AP Medical Writer | News | Comments

After an expert meeting this week, WHO said there is now enough information to conclude that the...

Roivant Acquires SB742457 from GlaxoSmithKline

December 29, 2014 2:42 pm | News | Comments

Roivant Neurosciences has entered into an...

View Sample

FREE Email Newsletter

GSK Reports Positive Outcome of Phase III Study of Shingles Vaccine Containing Agenus Adjuvant

December 18, 2014 10:58 am | News | Comments

Agenus and its partner GlaxoSmithKline have reported that the ZOE-50 Phase III study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.

GlaxoSmithKline Announces 900 Layoffs

December 4, 2014 8:37 am | Videos | Comments

GlaxoSmithKline released details of a restructuring program Wednesday, which included 900 layoffs.                          

Clovis Oncology and GSK to Collaborate on Oncology Clinical Trial

November 18, 2014 8:12 am | News | Comments

Clovis Oncology has entered into a clinical trial collaboration with GlaxoSmithKline to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC).      

Advertisement

EMA Advises on Development Plan for GSK Ebola Vaccine

October 29, 2014 11:15 am | News | Comments

The European Medicines Agency (EMA) has given scientific advice to GSK on its development plan for an Ebola vaccine. This is the first time in the current Ebola outbreak that EMA has given ‘rapid scientific advice’ using an accelerated procedure.

Swissmedic Approves Trial for Ebola Vaccine

October 28, 2014 7:35 am | by The Associated Press | News | Comments

The Swiss agency that regulates new drugs has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital. Swissmedic said the trial will be conducted among 120 volunteer participants with support from the U.N. World Health Organization.

GlaxoSmithKline Third Quarter 2014 Results Interview with CEO Sir Andrew Witty & CFO Simon Dingemans.

October 27, 2014 9:07 am | Videos | Comments

Interview with Sir Andrew Witty, CEO, and Simon Dingemans, CFO announcing the company's Q3 2014 results including a restructuring of the business and a possible partial IPO of ViiV Healthcare.          

Drugmakers Bet on Ebola Vaccines, Treatments

October 26, 2014 9:33 am | by Matthew Perrone - Associated Press - Associated Press | News | Comments

Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.    

WHO: Millions of Ebola Vaccine Doses Ready in 2015

October 24, 2014 11:38 am | by Maria Cheng - AP Medical Writer - Associated Press | News | Comments

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. Still, the agency warned it's not clear whether any of these will work against the deadly virus that has...

Advertisement

Isis Pharmaceuticals Earns $18M From GSK for Advancing ISIS-TTR Rx

October 9, 2014 8:14 am | News | Comments

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.  Including this $18M milestone payment, Isis has generated $45M of the $70M in upfront and milestone payments Isis is eligible to earn for advancing ISIS-TTRRx in development.

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.

Drug Firms Redirect Sales Pitch to Hospitals

October 3, 2014 8:40 am | Videos | Comments

Pharmaceutical companies are refining their sales strategy. GlaxoSmithKline's Dierdre Connelly discusses why with WSJ's Tanya Rivero.                    

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 10:48 am | News | Comments

The National Institute of Allergy and Infectious Diseases says an experimental Ebola vaccine is being processed at a facility in Frederick. The vaccine is a joint project between the federal agency and GlaxoSmithKline.      

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

October 1, 2014 8:35 am | News | Comments

The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumor types.        

Advertisement

Analyst: GSK's $490M Fine to Spark Pharma Strategy Shift in Emerging Markets

September 24, 2014 11:21 am | News | Comments

The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.           

Avalon Ventures and GlaxoSmithKline Launch Two New Companies

September 22, 2014 8:08 am | News | Comments

Silarus Therapeutics and Thyritope Biosciences each will receive up to $10M in Series A financing and R&D support from Avalon Ventures and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, the community of innovation established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.

China Fines GSK $492M for Bribery

September 19, 2014 5:47 am | by Joe Mcdonald - AP Business Writer - Associated Press | News | Comments

A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.

First UK Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:51 pm | by The Associated Press | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Ruth Atkins, 48, got the injection on Wednesday in Oxford, the first of 60 healthy volunteers in the U.K. who will receive the vaccine.

Monkey Study: Ebola Vaccine Works, Needs Booster

September 8, 2014 8:13 am | by LAURAN NEERGAARD, AP Medical Writer | News | Comments

New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way.            

US to Begin Safety Testing Ebola Vaccine Next Week

August 28, 2014 9:26 am | by SETH BORENSTEIN, AP Science Writer | News | Comments

The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. It will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.

Ligand Partner GlaxoSmithKline Receives FDA Approval for Promacta®/Revolade™

August 27, 2014 8:07 am | News | Comments

Ligand Pharmaceuticals Incorporated announced that its partner GlaxoSmithKline has received approval of a supplemental New Drug Application (sNDA) for the once-daily use of Promacta®/Revolade™ (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).

Health Canada OKs GSK's Plan to Fix Quebec Flu Vaccine Plant Problems

August 12, 2014 8:15 am | by Helen Branswell, The Canadian Press | News | Comments

Health Canada says it has approved a plan by GlaxoSmithKline to fix contamination problems it has been experiencing at its Ste. Foy, Que., flu vaccine production plant. The department says GSK's action plan and the timelines proposed in it are satisfactory.

China Jails British-US Investigator Couple

August 8, 2014 1:29 pm | News | Comments

A Briton and an American were sentenced to prison on Friday on charges of illegally trading in the personal details of Chinese citizens after they testified they bought such information to help companies combat fraud.          

British-US Investigative Couple on Trial in China

August 8, 2014 12:30 am | by The Associated Press | News | Comments

A British man on trial with his American wife for illegally obtaining and selling private information about Chinese nationals says he buys such information from other consulting companies. Peter William Humphrey made the comments Friday after his trial opened in Shanghai.

China to Put Glaxo Investigators On Trial

July 29, 2014 5:30 am | by The Associated Press | News | Comments

A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."

GSK Asks European Regulator to OK Malaria Shot

July 24, 2014 8:18 am | News | Comments

The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading